ECSP044862A - Pirenzepine ophthalmic gel - Google Patents

Pirenzepine ophthalmic gel

Info

Publication number
ECSP044862A
ECSP044862A EC2004004862A ECSP044862A ECSP044862A EC SP044862 A ECSP044862 A EC SP044862A EC 2004004862 A EC2004004862 A EC 2004004862A EC SP044862 A ECSP044862 A EC SP044862A EC SP044862 A ECSP044862 A EC SP044862A
Authority
EC
Ecuador
Prior art keywords
ophthalmic gel
pirenzepine
pirenzepine ophthalmic
gel
pyrenzepine
Prior art date
Application number
EC2004004862A
Other languages
English (en)
Inventor
Harun Takruri
Original Assignee
Valley Forge Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valley Forge Pharmaceuticals filed Critical Valley Forge Pharmaceuticals
Publication of ECSP044862A publication Critical patent/ECSP044862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Es un objeto primario de la presente invención proporcionar una formulación oftálmica acuosa, para tratar la miopía, ésta formulación comprende la pirenzepina en combinación con un portador de gel, aceptable farmacéuticamente
EC2004004862A 2001-05-25 2004-01-23 Pirenzepine ophthalmic gel ECSP044862A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29373101P 2001-05-25 2001-05-25

Publications (1)

Publication Number Publication Date
ECSP044862A true ECSP044862A (es) 2004-03-23

Family

ID=23130330

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004862A ECSP044862A (es) 2001-05-25 2004-01-23 Pirenzepine ophthalmic gel

Country Status (17)

Country Link
US (2) US20040137069A1 (es)
EP (1) EP1397132A4 (es)
JP (1) JP2004531569A (es)
KR (1) KR20040018380A (es)
CN (1) CN1509172A (es)
BR (1) BR0210013A (es)
CA (1) CA2447562A1 (es)
EC (1) ECSP044862A (es)
HU (1) HUP0304071A2 (es)
IL (1) IL158904A0 (es)
MX (1) MXPA03010655A (es)
NO (1) NO20035224D0 (es)
NZ (1) NZ529615A (es)
PL (1) PL366924A1 (es)
RU (1) RU2297831C2 (es)
WO (1) WO2002096418A1 (es)
ZA (1) ZA200309791B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573673A1 (en) * 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
JP4963359B2 (ja) * 2005-01-12 2012-06-27 ロート製薬株式会社 眼局所適用製剤
SG170806A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Nasolacrimal drainage system implants for drug therapy
WO2008083118A1 (en) * 2006-12-26 2008-07-10 Qlt Plug Delivery, Inc. Drug delivery implants for inhibition of optical defects
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
ES2533359T3 (es) 2007-09-07 2015-04-09 Mati Therapeutics Inc. Núcleos de fármaco para liberación sostenida de agentes terapéuticos
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
NO2632468T3 (es) * 2010-10-25 2018-05-12
WO2012123515A1 (en) * 2011-03-14 2012-09-20 Drug Delivery Solutions Limited An ophthalmic composition
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
CN105663137A (zh) * 2016-01-14 2016-06-15 王真 哌仑西平在制备治疗脓毒症疾病的药物中的应用
JP6590860B2 (ja) * 2016-05-25 2019-10-16 シンガポール ヘルス サービシーズ ピーティーイー リミテッド アトロピン含有水性組成物
KR20200083976A (ko) * 2017-11-03 2020-07-09 알콘 인코포레이티드 눈 장애의 치료를 위한 아자바이시클로 및 디아제핀 유도체
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
CA3133646A1 (en) * 2019-03-26 2020-10-01 Winsantor, Inc. Topical formulations for treatment of peripheral neuropathies
WO2020251926A1 (en) * 2019-06-10 2020-12-17 Jenivision Inc. Methods and formulations for treating vision disorders
JP2022541152A (ja) * 2019-07-11 2022-09-22 ユニバーシティー オブ ユタ リサーチ ファウンデーション 多形態眼球製剤および治療法
KR102808906B1 (ko) * 2021-06-18 2025-05-19 대우제약 주식회사 고점도 점안제를 무균여과하는 방법
CN117338787A (zh) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 一种眼用药物组合物及其制备方法
WO2025171327A1 (en) * 2024-02-09 2025-08-14 Levation Pharma Ltd. Methods for producing dermatological gel compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
ES2136686T3 (es) * 1989-06-21 1999-12-01 Univ Pennsylvania Tratamiento y control de desarrollo ocular con agonistas colinergicos.
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
SU1827797A3 (ru) * 1991-04-30 1996-05-20 Н.Б. Леонидов Лекарственный препарат для анестезии глаз
US5461808A (en) * 1993-02-08 1995-10-31 Fritts; Robert W. Table top backlit display
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
RU2135129C1 (ru) * 1998-11-18 1999-08-27 Ларионов Евгений Викторович Глазные капли "корнеалон-плюс"
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia

Also Published As

Publication number Publication date
ZA200309791B (en) 2004-10-04
CA2447562A1 (en) 2002-12-05
EP1397132A4 (en) 2006-12-13
US20060188576A1 (en) 2006-08-24
NO20035224D0 (no) 2003-11-24
PL366924A1 (en) 2005-02-07
HUP0304071A2 (hu) 2004-04-28
JP2004531569A (ja) 2004-10-14
IL158904A0 (en) 2004-05-12
BR0210013A (pt) 2004-08-10
CN1509172A (zh) 2004-06-30
RU2003136735A (ru) 2005-03-27
WO2002096418A1 (en) 2002-12-05
KR20040018380A (ko) 2004-03-03
RU2297831C2 (ru) 2007-04-27
MXPA03010655A (es) 2007-06-22
US20040137069A1 (en) 2004-07-15
NZ529615A (en) 2005-07-29
EP1397132A1 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
ECSP044862A (es) Pirenzepine ophthalmic gel
HN1999000015A (es) Tratamiento para una disfuncion sexual femenina
TR200102711T2 (tr) Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
AU3831301A (en) Method for treating ocular pain
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
DK1496912T3 (da) Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
DE60331638D1 (de) Keratin-netzwerke enthaltende wundverbände für gewebedefekte
CY1106409T1 (el) Παραγωγα κινολινης
HK1046631A1 (zh) 含有酮替芬的眼药组合物
NO20052751D0 (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
CR7198A (es) Tableta que contiene cetirizina y pseudoefedrina
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
EA200400436A1 (ru) Медикаменты для профилактики и лечения бромидроза
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários